ERBB2 and triple-negative breast carcinoma: We used DIA to quantify CD68 (pan-macrophage marker), CD163 (M2-like TAM marker), CSF-1R (colony-stimulating factor 1 receptor; M2-like TAM marker) and CD206 (M2-like TAM marker) positive cells in a large, well-characterized series of Luminal-A, Luminal-B, human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancers (TNBC).